Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

British Journal of Cancer

Volumn 89, Issue 12, 2003, Pages 2234-2243

  Repp, R ^a   Van Ojik, H H ^b   Valerius, T ^a   Groenewegen, G ^b   Wieland, G ^a   Oetzel, C ^a   Stockmeyer, B ^a   Becker, W ^c   Eisenhut, M ^g   Steininger, H ^d   Deo, Y M ^e   Blijham, G H ^b   Kalden, J R ^a   Van De Winkel, J G J ^b,f   Gramatzki, M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Hospital Friedrichshafen   (Germany)

^e MEDAREX INC   (United States)

^f GENMAB   (Netherlands)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Fc RI; G CSF; HER 2 neu; Immunotherapy; MDX H210

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY MDX H210; CD64 ANTIGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 6; MDX H210; MDX-H210; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD; BONE MARROW CELL; BREAST CANCER; BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CHILL; CLINICAL TRIAL; COHORT ANALYSIS; CYTOLYSIS; DENDRITIC CELL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; EFFECTOR CELL; FEMALE; FEVER; GENE OVEREXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; IN VITRO STUDY; MACROPHAGE; MAXIMUM TOLERATED DOSE; METHODOLOGY; MONOCYTE; PATHOLOGY; PHASE 1 CLINICAL TRIAL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR BIOPSY; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; CYTOKINES; FEMALE; FILGRASTIM; GENES, ERBB-2; HUMANS; IMMUNOTHERAPY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 10744225362     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601367     Document Type: Article

References (39)

1. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750-4755
2. Baselga J (2001) Clinical trials of Herceptin (trastuzumab). Eur J Cancer 37(Suppl. 1): S18-S24
3. Becker W, Fischbach W, Reiners C, Borner W (1986) Three-phase white blood cell scan: diagnostic validity in abdominal inflammatory diseases. J Nucl Med 27: 1109-1115
4. Brittenden J, Heys SD, Ross J, Eremin O (1996) Natural killer cells and cancer. Cancer 77: 1226-1243
5. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639
7. Dillman RO (1999) Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18: 465-471
8. Eisenhut M, Lehmann WD, Becker W, Behr T, Elser H, Strittmatter W, Steinstraesser A, Baum RP, Valerius T, Repp R, Deo YM (1996) Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulation. J Nucl Med 37: 362-370
9. Fleit HB, Wright SD, Unkeless JC (1982) Human neutrophil Fc gamma receptor distribution and structure. Proc Natl Acad Sci USA 79: 3275-3279
10. Ghetie V, Ward ES (2000) Multiple roles for the major histocompatibility complex class !-related receptor FcRn. Annu Rev Immunol 18: 739-766
11. Glennie MJ, McBride HM, Worth AT, Stevenson GT (1987) Preparation and performance of bispecific F(ab′γ)2 antibody containing thioether-linked Fab′γ fragments. J Immunol 139: 2367-2375
12. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW (1989) Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 143: 1650-1655
13. Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A (1995) Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85: 2482-2489
14. Honeychurch J, Tutt AL, Valerius T, Heijnen IAFM, van de Winkel JGJ, Glennie MJ (2000) Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 96: 3544-3552
15. Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339: 974-984
16. Houghton AN, Scheinberg DA (2000) Monoclonal antibody therapies - a 'constant' threat to cancer. Nat Med 6: 373-374
17. Lewis LD, Cole BF, Wallace PK, Fisher JL, Waugh M, Guyre PM, Fanger MW, Curnow RT, Kaufman PA, Ernstoff MS (2001) Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods 248: 149-165
18. Looney RJ, Abraham GN, Anderson CL (1986) Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 136: 1641-1647
19. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195
20. Pegram M, Slamon D (2000) Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 27: 13-19
21. Perussia B, Dayton ET, Lazarus R, Fanning V, Trinchieri G (1983) Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells. J Exp Med 158: 1092-1113
22. Pfister DG, Lipton A, Belt R, Motzer RJ, Winston C, Metz EM, Sherman EJ, Curnow RT (1999) A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAb) MDX-447 in patients with solid tumors. Proc Am Soc Clin Oncol 18: 433a
23. Posey JA, Raspet R, Verma U, Deo YM, Keller T, Marshall JL, Hodgson J, Mazumder A, Hawkins MJ (1999) A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother 22: 371-379
24. Pullarkat V, Deo YM, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber JS (1999) A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother 48: 9-21
25. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19: 275-290
26. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E (1991) Neutrophils express the high affinity receptor for IgG (FcγRI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 78: 885-889
27. Ring DB, Kassel JA, Hsieh-Ma ST, Bjorn MJ, Tringale F, Eaton AM, Reid SA, Frankel AE, Nadji M (1989) Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer. Cancer Res 49: 3070-3080
28. Segal DM, Weiner GJ, Weiner LM (1999) Bispecific antibodies in cancer therapy. Curr Opin Immunol 11: 558-562
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
30. Smith JA, Weidemann MJ (1993) Further characterization of the neutrophil oxidative burst by flow cytometry. J Immunol Methods 162: 261-268
31. Stockmeyer B, Elsasser D, Dechant M, Repp R, Gramatzki M, Glennie MJ, van de Winkel JGJ, Valerius T (2001) Mechanisms of G-CSF-or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods 248: 103-111
32. Stockmeyer B, Valerius T, Repp R, Heijnen IAFM, Buhring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JGJ (1997) Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu over-expressing breast cancer. Cancer Res 57: 696-701
33. Valerius T, Repp R, de Wit TPM, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JGJ (1993) Involvement of the high-affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82: 931-939
34. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo YM, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Marley TL, Arzivu C, Fanger MW (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13: 2281-2292
35. van de Vijver MJ (2001) Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 37(Suppl. 1): 11-17
36. van de Winkel JGJ, Capel PJA (1993) Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 14: 215-221
37. van Vugt MJ, Kleijmeer MJ, Keler T, Zeelenberg I, van Dijk MA, Leusen JHW, Geuze HJ, van de Winkel JGJ (1999) The FcγRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR γ-chain. Blood 94: 808-817
38. Venter DJ, Tuzi NL, Kumar S, Gullick WJ (1987) Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 2: 69-72
39. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169: 333-338